A Systems View Across Time and Space
 | DiMasi OOP-CE (high) | Sertkaya CP-CE (low) | DiMasi OOP-Bio (high) | Sertkaya CP-Bio (low) |
---|---|---|---|---|
a. Abbreviated cost estimate | ||||
Registration | 1.3 | 1.3 | 1.3 | 1.3 |
Phase III | 255.4 | 25 | 255.4 | 25 |
Phase II | 58.6 | 7 | 58.6 | 7 |
Phase I | 25.3 | 2 | 25.3 | 2 |
Preclinical | 110 | 7 | 159 | 10 |
Discovery | 119 | 6 | 119 | 6 |
Total cost | 569.6 | 48.3 | 618.6 | 51.3 |
b. FEC cost estimate | ||||
Manufacturing costs | 400 | 400 | 400 | 400 |
Facility costs | 65 | 65 | 350 | 350 |
Launch/post-market R&D | 350 | 350 | 350 | 350 |
Registration | 1.3 | 1.3 | 1.3 | 1.3 |
Add. HTA CTs | 510.8 | 50 | 510.8 | 50 |
Phase III | 255.4 | 25 | 255.4 | 25 |
Phase II | 58.6 | 7 | 58.6 | 7 |
Phase I | 25.3 | 2 | 25.3 | 2 |
Preclinical | 110 | 7 | 159 | 10 |
Discovery | 119 | 6 | 119 | 6 |
Total | 1895.4 | 913.3 | 2229.4 | 1201.3 |